Information Provided By: 
Fly News Breaks for February 6, 2017
NXTM
Feb 6, 2017 | 06:19 EDT
Jefferies analyst Raj Denhoy raised his price target for NxStage Medical to $38 saying home hemodialysis in skilled nursing facilities represents a "significant opportunity" for the company. There are an estimated 50,000 patients in skilled nursing facilities on dialysis, and bringing treatment to them rather than transporting them to a clinic is both clinically and financially beneficial, Denhoy tells investors in a research note. He sees NxStage as "disproportionally" benefiting from this opportunity and keeps a Buy rating on the shares.
News For NXTM From the Last 2 Days
There are no results for your query NXTM
